STATCenter·
STAT+: AstraZeneca invests $2 billion in Summit Therapeutics
AstraZeneca is teaming up with Summit Therapeutics to test its PD-1/VEGF bispecific ivonescimab alongside AstraZeneca’s antibody-drug conjugates.
Read at STAT →
Health · 1 sources covering this
STAT+: AstraZeneca invests $2 billion in Summit Therapeutics
AstraZeneca is teaming up with Summit Therapeutics to test its PD-1/VEGF bispecific ivonescimab alongside AstraZeneca’s antibody-drug conjugates.
Coverage spectrum
0 L · 1 C · 0 R
How 1 sources are covering this
Embed this bias spectrum on your site
Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.
<iframe src="https://statesidedaily.com/embed/cluster/56408b1691ff9058165a2431243cdb872a76b7a6" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="STAT+: AstraZeneca invests $2 billion in Summit Therapeutics"></iframe>
